{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:53:20Z","timestamp":1772186000461,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0009583","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000}}],"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016-05780"],"award-info":[{"award-number":["2016-05780"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swiss Tropical and Public Health Institute"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>The polyamine synthesis inhibitor eflornithine is a recommended treatment for the neglected tropical disease Gambian human African trypanosomiasis in late stage. This parasitic disease, transmitted by the tsetse fly, is lethal unless treated. Eflornithine is administered by repeated intravenous infusions as a racemic mixture of L-eflornithine and D-eflornithine. The study compared the<jats:italic>in vitro<\/jats:italic>antitrypanosomal activity of the two enantiomers with the racemic mixture against three<jats:italic>Trypanosoma brucei gambiense<\/jats:italic>strains. Antitrypanosomal<jats:italic>in vitro<\/jats:italic>activity at varying drug concentrations was analysed by non-linear mixed effects modelling. For all three strains, L-eflornithine was more potent than D-eflornithine. Estimated 50% inhibitory concentrations of the three strains combined were 9.1 \u03bcM (95% confidence interval [8.1; 10]), 5.5 \u03bcM [4.5; 6.6], and 50 \u03bcM [42; 57] for racemic eflornithine, L-eflornithine and D-eflornithine, respectively. The higher<jats:italic>in vitro<\/jats:italic>potency of L-eflornithine warrants further studies to assess its potential for improving the treatment of late-stage Gambian human African trypanosomiasis.<\/jats:p>","DOI":"10.1371\/journal.pntd.0009583","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T17:41:05Z","timestamp":1626111665000},"page":"e0009583","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Enantiospecific antitrypanosomal in vitro activity of eflornithine"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4422-6226","authenticated-orcid":true,"given":"Mikael","family":"Boberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Cal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-7302","authenticated-orcid":true,"given":"Marcel","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasmus","family":"Jansson-L\u00f6fmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3122-1941","authenticated-orcid":true,"given":"Pascal","family":"M\u00e4ser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"issue":"5","key":"pntd.0009583.ref001","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1067\/mjd.2001.117853","article-title":"The eflornithine story","volume":"45","author":"PE Coyne","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"4467","key":"pntd.0009583.ref002","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1126\/science.6775372","article-title":"Polyamine metabolism: a potential therapeutic target in trypanosomes","volume":"210","author":"CJ Bacchi","year":"1980","journal-title":"Science (New York, NY)."},{"key":"pntd.0009583.ref003","unstructured":"WHO. WHO model list of essential medicines, 16th list March 2009. 2009;Available from www.who.int\/medicines\/publications\/essentialmedicines\/en\/, Accessed Feb 8, 2021."},{"issue":"9683","key":"pntd.0009583.ref004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"G Priotto","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"pntd.0009583.ref005","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1371\/journal.pntd.0000064","article-title":"Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series","volume":"1","author":"F Checchi","year":"2007","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"pntd.0009583.ref006","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/522982","article-title":"Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo","volume":"45","author":"G Priotto","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"10","key":"pntd.0009583.ref007","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/jama.1991.03460100029008","article-title":"From the Food and Drug Administration","volume":"265","author":"SL Nightingale","year":"1991","journal-title":"Jama"},{"issue":"5","key":"pntd.0009583.ref008","doi-asserted-by":"crossref","first-page":"e0008261","DOI":"10.1371\/journal.pntd.0008261","article-title":"Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2018","volume":"14","author":"JR Franco","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0009583.ref009","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00228-004-0759-7","article-title":"The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness","volume":"60","author":"K Na-Bangchang","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"pntd.0009583.ref010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF00203544","article-title":"Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine","volume":"5","author":"CA Griffin","year":"1987","journal-title":"Invest New Drugs"},{"issue":"Pt 2","key":"pntd.0009583.ref011","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/bj20030382","article-title":"Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine","volume":"375","author":"N Qu","year":"2003","journal-title":"Biochem J"},{"issue":"2","key":"pntd.0009583.ref012","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1128\/AAC.04101-14","article-title":"Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness","volume":"59","author":"R Jansson-Lofmark","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"37","key":"pntd.0009583.ref013","doi-asserted-by":"crossref","first-page":"23885","DOI":"10.1021\/acsomega.0c03121","article-title":"Chiral chromatographic isolation on milligram scale of the human African trypanosomiasis treatment D- and L-eflornithine","volume":"5","author":"M Boberg","year":"2020","journal-title":"ACS Omega"},{"issue":"3","key":"pntd.0009583.ref014","first-page":"134","article-title":"Epidemiological studies on the animal reservoir of gambiense sleeping sickness. Part II. Parasitological and immunodiagnostic examination of the human population.","volume":"32","author":"P Felgner","year":"1981","journal-title":"Tropenmedizin und Parasitologie"},{"issue":"2\u20133","key":"pntd.0009583.ref015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.actatropica.2007.07.007","article-title":"Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate","volume":"104","author":"N Maina","year":"2007","journal-title":"Acta tropica"},{"issue":"4","key":"pntd.0009583.ref016","doi-asserted-by":"crossref","first-page":"e1025","DOI":"10.1371\/journal.pntd.0001025","article-title":"Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice","volume":"5","author":"PP Pyana","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0009583.ref017","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2307\/3282883","article-title":"Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers","volume":"75","author":"H Hirumi","year":"1989","journal-title":"J Parasitol"},{"issue":"2","key":"pntd.0009583.ref018","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0001-706X(97)00079-X","article-title":"The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro","volume":"68","author":"B Raz","year":"1997","journal-title":"Acta tropica"},{"issue":"1","key":"pntd.0009583.ref019","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/md8010047","article-title":"Inhibitory activity of marine sponge-derived natural products against parasitic protozoa.","volume":"8","author":"I Orhan","year":"2010","journal-title":"Mar Drugs."},{"issue":"4","key":"pntd.0009583.ref020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0035-9203(93)90044-Q","article-title":"Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness","volume":"87","author":"F Milord","year":"1993","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0009583.ref021","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/s00436-002-0766-5","article-title":"Eflornithine for the treatment of human African trypanosomiasis","volume":"90","author":"C Burri","year":"2003","journal-title":"Parasitol Res"},{"issue":"5","key":"pntd.0009583.ref022","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","article-title":"Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents","volume":"21","author":"E Asin-Prieto","year":"2015","journal-title":"J Infect Chemother"},{"issue":"12","key":"pntd.0009583.ref023","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1128\/AAC.00287-13","article-title":"Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization","volume":"57","author":"NJ White","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pntd.0009583.ref024","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12936-019-3056-8","article-title":"Anti-malarial ozonides OZ439 and OZ609 tested at clinically relevant compound exposure parameters in a novel ring-stage survival assay","volume":"18","author":"A Walz","year":"2019","journal-title":"Malar J."},{"issue":"3","key":"pntd.0009583.ref025","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4269\/ajtmh.1987.37.525","article-title":"Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Cote d\u2019Ivoire","volume":"37","author":"F Doua","year":"1987","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0009583.ref026","unstructured":"WHO. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. 2019."},{"issue":"2","key":"pntd.0009583.ref027","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/cpt.1846","article-title":"Does in vitro potency predict clinically efficacious concentrations?","volume":"108","author":"R Jansson-Lofmark","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"pntd.0009583.ref028","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1471-4159.2008.05706.x","article-title":"The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain","volume":"107","author":"L Sanderson","year":"2008","journal-title":"J Neurochem"},{"issue":"3","key":"pntd.0009583.ref029","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF00255762","article-title":"Brain, CSF, and tumor pharmacokinetics of alpha-difluoromethylornithine in rats and dogs","volume":"10","author":"VA Levin","year":"1983","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"pntd.0009583.ref030","first-page":"398","article-title":"Une mol\u00e9cule nouvelle en th\u00e9rapeutique antiparasitaire: L\u2019alpha-difluorom\u00e9thylonrithine [A new molecule in antiparasitic therapy: alpha-difluoromethylornithine].","volume":"35","author":"Y Furet","year":"1987","journal-title":"Pathologie-biologie"},{"issue":"5","key":"pntd.0009583.ref031","doi-asserted-by":"crossref","first-page":"e1618","DOI":"10.1371\/journal.pntd.0001618","article-title":"Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei","volume":"6","author":"IM Vincent","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"pntd.0009583.ref032","doi-asserted-by":"crossref","first-page":"e1001204","DOI":"10.1371\/journal.ppat.1001204","article-title":"A molecular mechanism for eflornithine resistance in African trypanosomes","volume":"6","author":"IM Vincent","year":"2010","journal-title":"PLoS Pathog"},{"issue":"1","key":"pntd.0009583.ref033","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1042\/BJ20140719","article-title":"Trypanosoma brucei eflornithine transporter AAT6 is a low-affinity low-selective transporter for neutral amino acids","volume":"463","author":"C Mathieu","year":"2014","journal-title":"Biochem J"},{"key":"pntd.0009583.ref034","unstructured":"WHO. Accelerating Work to overcome the global impact of neglected tropical diseases: A roadmap for implementation. WHO Executive Summary [Internet]. 2012:[1\u201322 pp.]. Available from: http:\/\/whqlibdoc.who.int\/hq\/2012\/WHO_HTM_NTD_2012.1_eng.pdf, Accessed on 8 Feb, 2021."},{"issue":"8820","key":"pntd.0009583.ref035","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/0140-6736(92)92180-N","article-title":"Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness","volume":"340","author":"F Milord","year":"1992","journal-title":"Lancet"},{"issue":"5","key":"pntd.0009583.ref036","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/0035-9203(85)90195-6","article-title":"Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial","volume":"79","author":"S Van Nieuwenhove","year":"1985","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"8573","key":"pntd.0009583.ref037","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(87)91131-7","article-title":"Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness","volume":"2","author":"J Pepin","year":"1987","journal-title":"Lancet"},{"issue":"3","key":"pntd.0009583.ref038","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0002-9343(87)90107-0","article-title":"Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. Results in five patients","volume":"82","author":"H Taelman","year":"1987","journal-title":"Am J Med"},{"issue":"1","key":"pntd.0009583.ref039","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10928-012-9293-x","article-title":"Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat","volume":"40","author":"CC Johansson","year":"2013","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"pntd.0009583.ref040","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1128\/AAC.00050-08","article-title":"Enantioselective and nonlinear intestinal absorption of eflornithine in the rat","volume":"52","author":"R Jansson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"10116","key":"pntd.0009583.ref041","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial","volume":"391","author":"V Mesu","year":"2018","journal-title":"Lancet"},{"key":"pntd.0009583.ref042","article-title":"New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice","author":"AK Lindner","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pntd.0009583.ref043","article-title":"New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story","volume":"5","author":"EA Dickie","year":"2020","journal-title":"Trop Med Infect Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0009583","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T23:12:51Z","timestamp":1699225971000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009583"}},"subtitle":[],"editor":[{"given":"Margaret A.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009583","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0009583","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]}}}